Breast Cancer Coverage from Every Angle

Sara A. Hurvitz, MD, on Potentially Practice-Changing Findings on T-DXd vs T-DM1 in Metastatic Breast Cancer

Posted: Thursday, December 8, 2022

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical implications of new survival data from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. In addition, patients treated with T-DXd had a 36% lower risk of death than those treated with T-DM1.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.